Benign Liver Tumours

Wanless, Ian R.; Frcpc,

doi:10.1002/9781444341294.ch34

Cited by 1 publication

(1 citation statement)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This tumour could therefore originate at a very early stage of hepatic differentiation. Our clinical and biological results are consistent with data from the literature (2,10,15,16,17). The rare tumours secreting β-hCG or testosterone are associated with early puberty (18).…”

Section: Discussionsupporting

confidence: 90%

Hepatoblastoma: Experience of the paediatric haematology and oncology department, Hassan II university hospital of Fez.

V. KASHAMA,

G. OVIEBO ANDO,

S. BOURAMDANE

et al. 2024

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Introduction: Hepatoblastoma is the most common malignant hepatic tumour in children. However, it is a rare disease, representing approximately 2% of childhood tumours. The treatment combines chemotherapy with surgical excision. The objective of this study was to describe the epidemiological, clinical, therapeutic and progressive aspects of hepatoblastoma treated in the paediatric haematology and oncology department at the University Hospital Hassan II of Fès. Patients and Methods: This was a descriptive and retrospective study conducted over a 11-year period. All patients aged 0 to 15 years who were admitted and treated for hepatoblastoma were included. Results: 24 patients met the study criteria, including 9 boys and 15 girls. The average age at diagnosis was 11.52 months ± 4.9. The most common reason for consultation was abdominal distension. Hepatomegaly was observed in 50% of cases. The average tumour size was 116 mm. At the time of diagnosis, one-third of patients had pulmonary metastases, and all patients were classified as high risk. Therapeutically, 19 patients (79.17%) received chemotherapy and 16 (66.67%) underwent surgery. On the evolutionary level, we observed a recovery without events in 10 (41.67%) patients. Conclusion: hepatoblastoma is a rare tumour, but remains the most common hepatic tumour in children. Despite progress in diagnostic and therapeutic means, the mortality rate is significant.

show abstract